A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
We explored the therapeutic effects of dinaciclib, a cyclin-dependent kinase (CDK) inhibitor, in the treatment of thyroid cancer.Seven cell lines originating from three pathologic types of thyroid cancer (papillary, follicular and anaplastic) were studied. The cytotoxicity of dinaciclib was measured...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
Public Library of Science (PLoS)
2017-01-01
|
| Sraith: | PLoS ONE |
| Rochtain ar líne: | http://europepmc.org/articles/PMC5312924?pdf=render |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|